Gyre Therapeutics, Inc. Share Price
GYREGyre Therapeutics, Inc. Stock Performance
Open $6.14 | Prev. Close $6.28 | Circuit Range N/A |
Day Range $6.03 - $6.14 | Year Range $6.03 - $11.61 | Volume 2,583 |
Average Traded $6.09 |
Gyre Therapeutics, Inc. Share Price Chart
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
19-May-26 | $6.37 | $6.28 | -5.28% |
15-May-26 | $6.69 | $6.63 | -5.76% |
14-May-26 | $7.37 | $7.04 | -3.43% |
13-May-26 | $7.31 | $7.29 | +0.07% |
12-May-26 | $7.24 | $7.28 | +1.82% |
11-May-26 | $7.16 | $7.15 | -3.25% |
08-May-26 | $7.45 | $7.39 | +4.60% |
FAQs on Gyre Therapeutics, Inc. Share Price
Can I buy Gyre Therapeutics, Inc. shares in India?
What is the share price of Gyre Therapeutics, Inc.?
What is the 5 year returns of Gyre Therapeutics, Inc.?
What are the high & low stock price of Gyre Therapeutics, Inc. today?
What is the 52-week high and low of Gyre Therapeutics, Inc. stock?